Genedrive (GDR) AI Stock Analysis

• Market Cap: £8.75M
• Dividend Yield: N/A
• Average Volume (3M): 2.78M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.23
• Revenue Growth: 125.37%
• EPS Growth: 22.47%
• Country: UK
• Employees: 43
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.03
• Shares Outstanding: 624,895,400
• 10 Day Avg. Volume: 1,423,900
• 30 Day Avg. Volume: 2,778,510
• PEG Ratio: 3.53
• Price to Book (P/B): 6.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £1.50
• Price Target Upside: 7.14% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: 1.50p ▲(7.14%Upside)

Genedrive's stock score is primarily influenced by its strong revenue growth and a solid balance sheet, despite challenges in profitability and cash flow. Technical analysis shows a bearish trend but with neutral momentum indicators. Recent positive corporate events provide a minor uplift to the overall score.

Genedrive Business Overview & Revenue Model

Company Description

genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small polymerase chain reaction, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for the rapid determination of military biothreats from pathogens; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.

How the Company Makes Money

Genedrive generates revenue primarily through the sale of its diagnostic products and platforms. The company sells its Genedrive® instruments and associated assays, which are used by healthcare providers, laboratories, and research institutions. Revenue streams include direct sales, distribution partnerships, and collaborations with healthcare organizations and governmental bodies. Additionally, Genedrive may receive funding and grants for development projects and collaborations in the development of bespoke diagnostic solutions. Strategic partnerships with industry players and public health organizations also contribute to its earnings by expanding market reach and facilitating the adoption of its diagnostic technologies.

Genedrive Financial Statement Overview

Summary

Genedrive has demonstrated significant revenue growth but continues to face profitability challenges with negative profit margins. The balance sheet is relatively strong with low leverage and a high equity ratio. Cash flows are still negative, but there are signs of improvement in free cash flow. Overall, the company needs to focus on turning revenue growth into profitability while maintaining its strong balance sheet.

Income Statement

The company shows a significant increase in revenue from the previous year, with a growth rate of over 800%. However, the net profit margin remains negative at -1412%, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio is low, suggesting low leverage and manageable debt levels. The return on equity is negative due to negative net income, but the equity ratio is healthy at approximately 79%, indicating a strong equity position relative to total assets.

Cash Flow

Operating cash flow remains negative, indicating cash outflows from operations. Despite this, the free cash flow has improved slightly from the previous year, although it is still negative. The operating cash flow to net income ratio is positive, suggesting better cash flow management relative to net income.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	613.00K	501.00K	55.00K	49.00K	687.00K	1.06M
Gross Profit	441.00K	254.00K	-199.00K	-3.82M	-3.82M	-3.61M
EBITDA	-7.71M	-7.49M	-5.70M	-5.37M	-1.37M	-19.52M
Net Income	-7.37M	-7.08M	-5.15M	-4.67M	-691.00K	-19.42M
Balance Sheet
Total Assets	4.01M	6.80M	4.51M	6.62M	4.88M	10.45M
Cash, Cash Equivalents and Short-Term Investments	2.10M	5.19M	2.60M	4.59M	2.57M	8.22M
Total Debt	0.00	19.00K	241.00K	16.00K	119.00K	11.60M
Total Liabilities	936.00K	1.44M	2.47M	1.01M	1.28M	13.79M
Stockholders Equity	3.07M	5.36M	2.04M	5.61M	3.59M	-3.34M
Cash Flow
Free Cash Flow	-4.42M	-3.80M	-3.83M	-4.67M	-5.29M	-3.83M
Operating Cash Flow	-4.38M	-3.77M	-3.78M	-4.61M	-5.18M	-3.79M
Investing Cash Flow	-38.00K	1.00K	-37.00K	45.00K	33.00K	-40.00K
Financing Cash Flow	5.30M	6.36M	1.82M	6.58M	-456.00K	6.86M

Genedrive Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GDR, the sentiment is Negative. The current price of 1.4 is below the 20-day moving average (MA) of 1.42, below the 50-day MA of 1.42, and below the 200-day MA of 1.90, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.41 is Neutral, neither overbought nor oversold. The STOCH value of 36.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GDR.

Genedrive Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	60 Neutral	£12.10M	―	-62.83%	―	27.60%	1.35%
EMVC	56 Neutral	£13.61M	―	-18.57%	―	69.55%	-12.10%
OBD	53 Neutral	£10.28M	―	-333.59%	―	45.22%	55.71%
GDR	52 Neutral	£8.75M	―	-321.90%	―	125.37%	22.47%
Sector *	52 Neutral	$7.36B	-0.07	-63.77%	2.36%	16.35%	0.03%
VRCI	48 Neutral	£2.12M	―	-130.73%	―	226.45%	53.51%
PRM	44 Neutral	£8.97M	―		―	-2.80%	-38.55%

Genedrive Corporate Events

Genedrive’s CYP2C19 ID Kit Gains CE-Certification, Enhancing Market Reach

Genedrive plc announced the CE-certification of its Genedrive® CYP2C19 ID Kit under the European In Vitro Diagnostic Regulation, enabling its market presence in Europe and facilitating registrations in non-European countries. The kit is designed to rapidly identify patients unlikely to respond to the antiplatelet drug Clopidogrel, crucial in emergency healthcare settings. This certification is expected to enhance Genedrive’s market positioning, with potential to prevent recurrent stroke admissions and offer significant financial and productivity benefits to healthcare systems, particularly in the UK NHS.

Genedrive Expands Use of CYP2C19-ID Kit to Acute Coronary Syndrome

Genedrive plc announced that its Genedrive® CYP2C19-ID Kit will be used in a trial led by Manchester University Foundation Trust to support the expansion of its use to include Acute Coronary Syndrome (ACS). The trial, in collaboration with the GUIDE PCI programme and the British Heart Foundation, aims to assess the value and feasibility of rapid point-of-care CYP2C19 testing in cardiovascular disease to improve patient outcomes. This initiative aligns with recommendations from the American Heart Association for rapid genetic testing in cardiovascular indications and aims to integrate the Genedrive® CYP2C19-ID Kit into routine clinical practice. The trial will help establish the feasibility and value of this intervention, potentially leading to wider adoption across other centers, thus improving patient outcomes and optimizing healthcare resources.

Genedrive Faces Certification Delay for CYP2C19 ID Kit

Genedrive plc announced a one-month delay in the certification process of its Genedrive® CYP2C19 ID Kit under the European In Vitro Diagnostic Regulation. Despite the delay, the company remains focused on its growth strategy, which includes maximizing in-market sales, expanding geographically and through its product portfolio, and pursuing strategic mergers and acquisitions. The delay may impact the company’s operational timeline, but its strategic focus aims to strengthen its position in the pharmacogenetic testing market.